OBJECTIVE: We aimed to examine the clinical outcome in HIV-1-infected patients after more than 10 years of highly active antiretroviral therapy (HAART). METHODS: We analyzed data from 1,236 treatment-naïve adults who had started HAART. The primary endpoint was the yearly prevalence of death for AIDS-related causes (ARC) or for non-AIDS related causes (non-ARC). The data from our cohort were compared with that of the general population (GP) of our region. RESULTS: We observed that 116 patients died, and 58.6% of deaths were non-ARC. The death incidence decreased from 18.8% in 1998-1999 to 1.2% in 2008-2009. The leading causes of death were malignancies (35.3%), infections (21.6%), end-stage liver diseases (18.1%), and cardiovascular diseases (CVD) (6.9%). Yearly death rates were similar in the HIV-infected cohort and in the crude GP (odds ratio [OR] 1.1, 95% confidence interval [CI] 0.5-2.5), but when adjusted for age, HIV-infected patients showed a greater risk (OR 7.4, 95% CI 4.1-13.4). The difference was still highly significant when the analysis was restricted to non-ARCs (OR 4.3, 95% CI 2.07-9.2). Overall, malignancies (OR 5.7, 95% CI 2.6-12.8) and end-stage liver diseases (OR 35.0, 95% CI 15.5-78.8) were significantly more frequent than in the age-adjusted GP. CONCLUSIONS: Despite HAART, HIV-infected patients are at greater risk of death compared to a reference uninfected population.
OBJECTIVE: We aimed to examine the clinical outcome in HIV-1-infectedpatients after more than 10 years of highly active antiretroviral therapy (HAART). METHODS: We analyzed data from 1,236 treatment-naïve adults who had started HAART. The primary endpoint was the yearly prevalence of death for AIDS-related causes (ARC) or for non-AIDS related causes (non-ARC). The data from our cohort were compared with that of the general population (GP) of our region. RESULTS: We observed that 116 patients died, and 58.6% of deaths were non-ARC. The death incidence decreased from 18.8% in 1998-1999 to 1.2% in 2008-2009. The leading causes of death were malignancies (35.3%), infections (21.6%), end-stage liver diseases (18.1%), and cardiovascular diseases (CVD) (6.9%). Yearly death rates were similar in the HIV-infected cohort and in the crude GP (odds ratio [OR] 1.1, 95% confidence interval [CI] 0.5-2.5), but when adjusted for age, HIV-infectedpatients showed a greater risk (OR 7.4, 95% CI 4.1-13.4). The difference was still highly significant when the analysis was restricted to non-ARCs (OR 4.3, 95% CI 2.07-9.2). Overall, malignancies (OR 5.7, 95% CI 2.6-12.8) and end-stage liver diseases (OR 35.0, 95% CI 15.5-78.8) were significantly more frequent than in the age-adjusted GP. CONCLUSIONS: Despite HAART, HIV-infectedpatients are at greater risk of death compared to a reference uninfected population.
Authors: Ard van Sighem; Sven Danner; Azra C Ghani; Luuk Gras; Roy M Anderson; Frank de Wolf Journal: J Acquir Immune Defic Syndr Date: 2005-10-01 Impact factor: 3.731
Authors: Anil K Chaturvedi; Ruth M Pfeiffer; Leonard Chang; James J Goedert; Robert J Biggar; Eric A Engels Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: A Mocroft; R Brettle; O Kirk; A Blaxhult; J M Parkin; F Antunes; P Francioli; A D'Arminio Monforte; Z Fox; J D Lundgren Journal: AIDS Date: 2002-08-16 Impact factor: 4.177
Authors: A Antinori; A Ammassari; C Torti; P Marconi; M Andreoni; G Angarano; S Bonora; A Castagna; R Cauda; M Clerici; A d'Arminio Monforte; A De Luca; G Di Perri; M Galli; E Girardi; A Gori; A Lazzarin; S Lo Caputo; F Mazzotta; F Montella; C Mussini; C F Perno; M Puoti; G Rizzardini; S Rusconi; V Vullo; G Carosi Journal: Infection Date: 2009-05-28 Impact factor: 3.553
Authors: Thomas Powles; David Robinson; Justin Stebbing; Jonathan Shamash; Mark Nelson; Brian Gazzard; Sundhiya Mandelia; Henrik Møller; Mark Bower Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: AIDS Date: 2008-10-18 Impact factor: 4.632
Authors: S Leone; M Prosperi; S Costarelli; P Nasta; F Maggiolo; S Di Giambenedetto; A Saracino; M Di Pietro; A Gori Journal: Eur J Clin Microbiol Infect Dis Date: 2016-06-06 Impact factor: 3.267
Authors: Keri N Althoff; Lisa P Jacobson; Ross D Cranston; Roger Detels; John P Phair; Xiuhong Li; Joseph B Margolick Journal: J Gerontol A Biol Sci Med Sci Date: 2013-10-14 Impact factor: 6.053
Authors: Forrest Toegel; August F Holtyn; Sarah Pollock; Andrew M Rodewald; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: HIV Res Clin Pract Date: 2020-03-05
Authors: Shrinidhi Subramaniam; Carol-Ann Getty; August F Holtyn; Andrew Rodewald; Brian Katz; Brantley P Jarvis; Jeannie-Marie S Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: AIDS Behav Date: 2019-11
Authors: Charles P Brandt; David P Sheppard; Michael J Zvolensky; Erin E Morgan; J Hampton Atkinson; Steven Paul Woods Journal: J HIV AIDS Soc Serv Date: 2016-06-28